Analysis of Intestinal Defensin Expression in Acute GVHD

Analysis of Intestinal Defensin Expression in Patients With Acute Graft-versus-Host Disease (GVHD)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04522843

Enrollment

Registered

2020-08-21

Start date

2018-09-01

Completion date

2024-10-30

Last updated

2024-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GVHD,Acute, Morbus Crohn, Ulcerative Colitis

Brief summary

This study has the aim to analyze intestinal expression of endogenous antimicrobial peptides in patients with acute GVHD. The expression will be compared to intestinal expression of defensins in patients with colitis and patients without intestinal inflammation.

Detailed description

Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Acute GVHD is characterized by complex deficiencies of the mucosal antimicrobial barrier and intestinal dysbiosis, which contribute to disease pathogenesis. Defensins are endogenous epithelial cell-derived antimicrobial peptides, which can protect epithelial barrier integrity, shape the intestinal microbiota composition and contribute to host immunoregulation. Deregulated expression of defensins has been reported in patients with colitis, including Chron's Disease and ulcerative colitis. In this study, the investigators aim to analyze the expression of defensins in the intestine of patients with acute GVHD to study whether it is deregulated. The results will be valuable to study the role of defensins during acute GVHD pathogenesis or as potential biomarkers for disease activity.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* age ≥ 18 years * diagnostic endoscopy was performed * diagnosis results available * written informed consent * ability to understand the nature of the study and the study related procedures and to comply with them

Exclusion criteria

* age \< 18 years * gastrointestinal cancer * lack of informed consent

Design outcomes

Primary

Measure	Time frame	Description
Defensin Expression (mRNA)	3 years	Analysis of alpha-defensin and beta-defensin mRNA expression by realtime PCR (qRT-PCR)
Defensin Expression (peptide)	3 years	Analysis of alpha-defensin and beta-defensin levels by immunohistochemistry

Countries

Germany

Outcome results